b'<?xml version="1.0" ?>\n<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">\n<PubmedArticleSet>\n<PubmedArticle>\n    <MedlineCitation Status="In-Process" Owner="NLM">\n        <PMID Version="1">31432769</PMID>\n        <DateRevised>\n            <Year>2020</Year>\n            <Month>04</Month>\n            <Day>14</Day>\n        </DateRevised>\n        <Article PubModel="Print-Electronic">\n            <Journal>\n                <ISSN IssnType="Electronic">1461-7285</ISSN>\n                <JournalIssue CitedMedium="Internet">\n                    <Volume>33</Volume>\n                    <Issue>12</Issue>\n                    <PubDate>\n                        <Year>2019</Year>\n                        <Month>12</Month>\n                    </PubDate>\n                </JournalIssue>\n                <Title>Journal of psychopharmacology (Oxford, England)</Title>\n                <ISOAbbreviation>J. Psychopharmacol. (Oxford)</ISOAbbreviation>\n            </Journal>\n            <ArticleTitle>Transient receptor potential vanilloid 1 mediates cocaine reinstatement via the D1 dopamine receptor in the nucleus accumbens.</ArticleTitle>\n            <Pagination>\n                <MedlinePgn>1491-1500</MedlinePgn>\n            </Pagination>\n            <ELocationID EIdType="doi" ValidYN="Y">10.1177/0269881119864943</ELocationID>\n            <Abstract>\n                <AbstractText Label="PURPOSE">The transient receptor potential vanilloid 1 (TRPV1) is a nonselective cation channel that mediates synaptic modification in the nucleus accumbens (NAc). However, no study has yet examined the mechanism of TRPV1 in the NAc on cocaine reinstatement. We investigated the mechanism of TRPV1 in NAc on cocaine reinstatement using the conditioned place preference (CPP) test in mice.</AbstractText>\n                <AbstractText Label="METHODS">We examined the effect of capsazepine (5\xe2\x80\x89mg/kg, a TRPV1 antagonist, administered intraperitoneally (i.p.)), capsaicin (0.3\xe2\x80\x89mg/kg, a TRPV1 agonist, administered i.p.), and genetic deletion of TRPV1 on the reinstatement of cocaine-induced CPP (15\xe2\x80\x89mg/kg, administered i.p.). The expression of TRPV1 and Ca2<sup>+</sup>/calmodulin-mediated kinase II (CaMKII) in the NAc were determined after cocaine reinstatement. Microinjection of SB366791 (0.2\xe2\x80\x89ng, a selective TRPV1 antagonist) in the NAc was assessed on SKF-81297 (1\xe2\x80\x89\xc2\xb5g, D1-like dopamine (DA) receptor agonist) primed cocaine reinstatement.</AbstractText>\n                <AbstractText Label="RESULTS">Capsazepine suppressed and capsaicin potentiated cocaine CPP in the reinstatement phase. In addition, genetic deletion of TRPV1 inhibited cocaine-priming reinstatement. Cocaine reinstatement was mediated by increased TRPV1 expression in the NAc, which involves CaMKII. Microinjection of SB366791 in the NAc prevented the cocaine reinstatement evoked by microinjection of SKF-81297 in the NAc.</AbstractText>\n                <AbstractText Label="CONCLUSIONS">These findings suggest that activation of TRPV1 mediates the stimulation of D1-like DA receptors and CaMKII in the NAc, resulting in the facilitation of cocaine reinstatement behaviors. Thus, our findings reveal a previously unknown TRPV1 mechanism in the reinstatement to drugs of abuse.</AbstractText>\n            </Abstract>\n            <AuthorList CompleteYN="Y">\n                <Author ValidYN="Y">\n                    <LastName>You</LastName>\n                    <ForeName>In-Jee</ForeName>\n                    <Initials>IJ</Initials>\n                    <Identifier Source="ORCID">0000-0002-6557-5337</Identifier>\n                    <AffiliationInfo>\n                        <Affiliation>Department of Pharmacology, School of Pharmacy, Sungkyunkwan University, Suwon, Republic of Korea.</Affiliation>\n                    </AffiliationInfo>\n                    <AffiliationInfo>\n                        <Affiliation>Department of Neurobiology, Brudnick Neuropsychiatric Research Institute, University of Massachusetts Medical School, Worcester, MA, USA.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Hong</LastName>\n                    <ForeName>Sa-Ik</ForeName>\n                    <Initials>SI</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Department of Pharmacology, School of Pharmacy, Sungkyunkwan University, Suwon, Republic of Korea.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Ma</LastName>\n                    <ForeName>Shi-Xun</ForeName>\n                    <Initials>SX</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Department of Pharmacology, School of Pharmacy, Sungkyunkwan University, Suwon, Republic of Korea.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Nguyen</LastName>\n                    <ForeName>Thi-Lien</ForeName>\n                    <Initials>TL</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Department of Pharmacology, School of Pharmacy, Sungkyunkwan University, Suwon, Republic of Korea.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Kwon</LastName>\n                    <ForeName>Seung-Hwan</ForeName>\n                    <Initials>SH</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Department of Pharmacology, School of Pharmacy, Sungkyunkwan University, Suwon, Republic of Korea.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Lee</LastName>\n                    <ForeName>Seok-Yong</ForeName>\n                    <Initials>SY</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Department of Pharmacology, School of Pharmacy, Sungkyunkwan University, Suwon, Republic of Korea.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Jang</LastName>\n                    <ForeName>Choon-Gon</ForeName>\n                    <Initials>CG</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Department of Pharmacology, School of Pharmacy, Sungkyunkwan University, Suwon, Republic of Korea.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n            </AuthorList>\n            <Language>eng</Language>\n            <PublicationTypeList>\n                <PublicationType UI="D016428">Journal Article</PublicationType>\n                <PublicationType UI="D013485">Research Support, Non-U.S. Gov\'t</PublicationType>\n            </PublicationTypeList>\n            <ArticleDate DateType="Electronic">\n                <Year>2019</Year>\n                <Month>08</Month>\n                <Day>21</Day>\n            </ArticleDate>\n        </Article>\n        <MedlineJournalInfo>\n            <Country>United States</Country>\n            <MedlineTA>J Psychopharmacol</MedlineTA>\n            <NlmUniqueID>8907828</NlmUniqueID>\n            <ISSNLinking>0269-8811</ISSNLinking>\n        </MedlineJournalInfo>\n        <CitationSubset>IM</CitationSubset>\n        <KeywordList Owner="NOTNLM">\n            <Keyword MajorTopicYN="Y">Ca2+/calmodulin-mediate</Keyword>\n            <Keyword MajorTopicYN="Y">D1-like dopamine receptors</Keyword>\n            <Keyword MajorTopicYN="Y">Transient receptor potential vanilloid 1</Keyword>\n            <Keyword MajorTopicYN="Y">cocaine reinstatement</Keyword>\n        </KeywordList>\n    </MedlineCitation>\n    <PubmedData>\n        <History>\n            <PubMedPubDate PubStatus="pubmed">\n                <Year>2019</Year>\n                <Month>8</Month>\n                <Day>23</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="medline">\n                <Year>2019</Year>\n                <Month>8</Month>\n                <Day>23</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="entrez">\n                <Year>2019</Year>\n                <Month>8</Month>\n                <Day>22</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n        </History>\n        <PublicationStatus>ppublish</PublicationStatus>\n        <ArticleIdList>\n            <ArticleId IdType="pubmed">31432769</ArticleId>\n            <ArticleId IdType="doi">10.1177/0269881119864943</ArticleId>\n        </ArticleIdList>\n    </PubmedData>\n</PubmedArticle>\n\n</PubmedArticleSet>'